Shares of McKesson Corporation fell sharply on Thursday, dropping -6.3% to $1,001.38, after the drug distribution giant delivered a quarter that looked strong on paper but exposed a soft spot investors couldn't ignore. McKesson Beat Every Number That Matters — So Why Are Investors Heading for the Exit?
Shares of McKesson tumbled -6.3% to $1,001.38 the day after the nation's largest drug distributor posted fiscal Q2 results that cleared Wall Street's bar on every headline metric — and then raised its full-year outlook. The sell-off erased roughly $8 billion in market value and signals that at a stock price near all-time highs, investors demand perfection across every business line.
The Top-Line Numbers Were Unambiguously Strong
McKesson reported consolidated revenues of $111.0 billion, up 8% year over year, and adjusted earnings per share of $11.68, up 18%.
The company beat the consensus EPS estimate of $10.72 by nearly a dollar.
Management raised full-year adjusted EPS guidance to $45.60–$46.40, up from $44.20–$45.00, with the new midpoint of $46.00 topping the Street's $44.66 forecast. On any other day, that combination would fuel a rally.
One Weak Spot Overshadowed Everything Else
Adjusted segment operating profit at Medical-Surgical Solutions fell 10% to $225 million, driven by lower contributions from the ambulatory care channel due to unfavorable product mix.
While revenues for the segment grew 5% to $3.1 billion , profitability shrank — a troubling signal because McKesson is actively separating this business into an independent, publicly traded company to sharpen its focus on higher-growth oncology and biopharma markets.
Analysts flagged the segment's margin compression as "a soft spot, particularly ahead of the planned separation." A unit heading toward an IPO-style spinoff under the name Wellverse needs to show improving economics to command a premium valuation on its own.
The Stock Had Already Priced In Good News
MCK hit a new 52-week high of $1,034.11 during the regular session on November 4 , the day results were released — a run-up of roughly 30% from its 52-week low of $723.68. The stock's forward P/E ratio sat near 28.6x , rich for a drug distribution business built on thin margins. That left no cushion for any disappointment, and the Medical-Surgical miss gave sellers an excuse to book profits.
Cash Returns Remain the Anchor
McKesson generated $3.1 billion in operating cash flow in the quarter and returned $3.6 billion to shareholders in the first half through $3.4 billion in buybacks and $198 million in dividends. That aggressive repurchase pace — shrinking the share count enough to boost per-share earnings — remains the core engine of the stock's long-term appeal, even as the Medical-Surgical stumble clouds the near-term narrative.